Histopathology Is Key to Interpreting Multiplex Molecular Test Results From Postmortem Minimally Invasive Tissue Samples.
MITS
TAC
TaqMan® array card
histopathology
minimally invasive tissue sampling
multiplex PCR
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
15 12 2021
15 12 2021
Historique:
entrez:
15
12
2021
pubmed:
16
12
2021
medline:
16
3
2022
Statut:
ppublish
Résumé
Minimally invasive tissue sampling (MITS) is an alternative to complete autopsy for determining causes of death. Multiplex molecular testing performed on MITS specimens poses challenges of interpretation, due to high sensitivity and indiscriminate detection of pathogenic, commensal, or contaminating microorganisms. MITS was performed on 20 deceased children with respiratory illness, at 10 timepoints up to 88 hours postmortem. Samples were evaluated by multiplex molecular testing on fresh tissues by TaqMan® Array Card (TAC) and by histopathology, special stains, immunohistochemistry (IHC), and molecular testing (PCR) on formalin-fixed, paraffin-embedded (FFPE) tissues. Results were correlated to determine overall pathologic and etiologic diagnoses and to guide interpretation of TAC results. MITS specimens collected up to 3 days postmortem were adequate for histopathologic evaluation and testing. Seven different etiologic agents were detected by TAC in 10 cases. Three cases had etiologic agents detected by FFPE or other methods and not TAC; 2 were agents not present on TAC, and 2 were streptococci that may have been species other than those present on TAC. Result agreement was 43% for TAC and IHC or PCR, and 69% for IHC and PCR. Extraneous TAC results were common, especially when aspiration was present. TAC can be performed on MITS up to 3 days after death with refrigeration and provides a sensitive method for detection of pathogens but requires careful interpretation in the context of clinicoepidemiologic and histopathologic findings. Interpretation of all diagnostic tests in aggregate to establish overall case diagnoses maximizes the utility of TAC in MITS.
Sections du résumé
BACKGROUND
Minimally invasive tissue sampling (MITS) is an alternative to complete autopsy for determining causes of death. Multiplex molecular testing performed on MITS specimens poses challenges of interpretation, due to high sensitivity and indiscriminate detection of pathogenic, commensal, or contaminating microorganisms.
METHODS
MITS was performed on 20 deceased children with respiratory illness, at 10 timepoints up to 88 hours postmortem. Samples were evaluated by multiplex molecular testing on fresh tissues by TaqMan® Array Card (TAC) and by histopathology, special stains, immunohistochemistry (IHC), and molecular testing (PCR) on formalin-fixed, paraffin-embedded (FFPE) tissues. Results were correlated to determine overall pathologic and etiologic diagnoses and to guide interpretation of TAC results.
RESULTS
MITS specimens collected up to 3 days postmortem were adequate for histopathologic evaluation and testing. Seven different etiologic agents were detected by TAC in 10 cases. Three cases had etiologic agents detected by FFPE or other methods and not TAC; 2 were agents not present on TAC, and 2 were streptococci that may have been species other than those present on TAC. Result agreement was 43% for TAC and IHC or PCR, and 69% for IHC and PCR. Extraneous TAC results were common, especially when aspiration was present.
CONCLUSIONS
TAC can be performed on MITS up to 3 days after death with refrigeration and provides a sensitive method for detection of pathogens but requires careful interpretation in the context of clinicoepidemiologic and histopathologic findings. Interpretation of all diagnostic tests in aggregate to establish overall case diagnoses maximizes the utility of TAC in MITS.
Identifiants
pubmed: 34910182
pii: 6460384
doi: 10.1093/cid/ciab772
pmc: PMC8672755
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
S351-S359Subventions
Organisme : Bill and Melinda Gates Foundation
ID : OPP1168515
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Sci Rep. 2018 Oct 31;8(1):16112
pubmed: 30382145
East Afr Med J. 2009 Dec;86(12 Suppl):S58-61
pubmed: 21591511
PLoS One. 2018 Oct 16;13(10):e0204867
pubmed: 30325924
J Pediatric Infect Dis Soc. 2014 Sep;3 Suppl 1:S2-6
pubmed: 25232473
N Engl J Med. 1981 Dec 10;305(24):1425-31
pubmed: 6272109
BMC Med. 2014 Feb 04;12:19
pubmed: 24495839
Ann Paediatr. 1953 Jan;180(1):1-21
pubmed: 13051050
Diagn Microbiol Infect Dis. 2016 Jan;84(1):80-86
pubmed: 26508103
Gates Open Res. 2020 May 28;4:55
pubmed: 33145479
PLoS Med. 2017 Jun 20;14(6):e1002318
pubmed: 28632735
Clin Infect Dis. 2019 Oct 9;69(Suppl 4):S311-S321
pubmed: 31598666
Am J Clin Pathol. 2019 Jun 5;152(1):36-49
pubmed: 31006817
J Pathol. 1988 Apr;154(4):365-70
pubmed: 3260275
Glob Health Action. 2020 Dec 31;13(1):1792682
pubmed: 32713325
Lancet. 2019 Aug 31;394(10200):757-779
pubmed: 31257127
PLoS Med. 2017 Jun 20;14(6):e1002317
pubmed: 28632739
Clin Microbiol Infect. 2019 May;25(5):570-579
pubmed: 30145399
J Virol. 1993 Sep;67(9):5360-6
pubmed: 8394453
Ann Glob Health. 2019 Jul 03;85(1):
pubmed: 31276331
J Infect Dis. 2012 May 15;205 Suppl 2:S340-6
pubmed: 22448024
Arch Dis Child. 2001 Jun;84(6):463-7
pubmed: 11369557
Clin Infect Dis. 2019 Oct 9;69(Suppl 4):S333-S341
pubmed: 31598661
Lancet Glob Health. 2020 Jul;8(7):e909-e919
pubmed: 32562647
Clin Infect Dis. 2019 Oct 9;69(Suppl 4):S351-S360
pubmed: 31598660
Clin Infect Dis. 2019 Oct 9;69(Suppl 4):S361-S373
pubmed: 31598659
J Clin Microbiol. 2011 Jun;49(6):2175-82
pubmed: 21471348